To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@mail.nih.gov along with the following information:

Your name, title, and organization
Study Number and Study Title
The specific dataset(s) you are requesting
The intended use or purpose of the data
Willingness to comply with the NIDA Datashare Registration Agreement

Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-MDS-0007

Division

DTMC

HEAL Study

Investigator(s)

Ann Anderson, M.D.

Title

Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence

Short Description

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

Release Date

Dec 04, 2014

Description

The primary objective of this study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 day prior to signing consent. It is hypothesized that bupropion, compared to placebo, will be associated with an increase in the proportion of subjects who achieve abstinence (confirmed by at least two methamphetamine negative urines) each week during the last two weeks (Weeks 11 and 12) for non-daily users as the primary outcome.

Keywords

Assessments

Addiction Severity Index Lite

Adult ADHD Investigator Symptom Rating Scale

Brief Substance Craving Scale

Clinical Global Impression Scales

HIV Risk-Taking Behaviour Scale

Hamilton – Depression Rating Scale